Riferimento farmaci
Pralsetinib
Pralsetinib is a medicine in the class oncology. It is used for non-small cell lung cancer.
- Classe del farmaco: Oncology
- Indicato per: non-small cell lung cancer
Ultimo aggiornamento Fonti: US FDA label
Per operatori sanitari — solo a scopo di riferimento. Questa pagina è una sintesi breve, non è un parere medico e non sostituisce il RCP ufficiale né il giudizio clinico. Verificare sempre prima di prescrivere o dispensare.
Il contenuto clinico di questa pagina è disponibile solo in inglese.
In breve
- Classe del farmaco
- Oncology
- Forme farmaceutiche comuni
- capsula
- Dosaggi comuni
- 100 mg
- Interazioni note
- 16 (Maggiore: 15 · Moderata: 1)
- Nomi commerciali
- 1
- Paesi e mercati
- 1
Per cosa si usa
Come agisce
Kinase inhibitor of wild-type RET and oncogenic RET fusions and mutations (IC50s less than 0.5 nM); inhibits downstream signaling that drives uncontrolled cell proliferation.
Dose abituale nell'adulto (sintesi del foglio illustrativo)
RET fusion-positive NSCLC or thyroid cancer: 400 mg orally once daily on an empty stomach (no food for at least 2 hours before and at least 1 hour after); continue until disease progression or unacceptable toxicity
Gravidanza e allattamento
- Gravidanza
- Unsafe Can cause fetal harm: in rats it caused malformations and embryo death below human exposure; no human data. Avoid in pregnancy; check pregnancy status. Women: non-hormonal contraception during treatment and for 2 weeks after (it may make hormonal methods fail); men: 1 week.
- Allattamento
- Unsafe No data on passage into milk; it is 97% protein bound, but its 22-hour half-life may allow build-up in the infant (LactMed). Do not breastfeed during treatment and for 1 week after the last dose.
Effetti indesiderati segnalati
- Musculoskeletal pain
- Constipation
- Hypertension
- Diarrhea
- Fatigue
- Edema
Avvertenze in evidenza
- May increase the risk of serious bacterial, fungal, viral and opportunistic infections, which can lead to hospitalization or death. Withhold, reduce the dose or permanently discontinue based on severity.
Chi deve prestare attenzione
- Serious infections, including opportunistic and fatal infections: monitor for signs and symptoms and treat appropriately.
- Interstitial lung disease/pneumonitis can be severe, life-threatening or fatal; withhold and investigate for acute or worsening respiratory symptoms.
- Hypertension: do not initiate in uncontrolled hypertension; monitor BP after 1 week and at least monthly thereafter.
Informare il farmacista o il medico di gravidanza o allattamento, malattie renali o epatiche, allergie e di ogni altro farmaco o integratore assunto.
Interazioni principali (16)
- Amobarbital + Pralsetinib Major
- Apalutamide + Pralsetinib Major
- Carbamazepine + Pralsetinib Major
- Chloramphenicol + Pralsetinib Major
- Clarithromycin + Pralsetinib Major
- Efavirenz + Pralsetinib Major
- Enzalutamide + Pralsetinib Major
- Itraconazole + Pralsetinib Major
- Ketoconazole + Pralsetinib Major
- Lorlatinib + Pralsetinib Major
Per gli utenti Pro+
Sblocca la pagina completa
Crei un account e avvii una prova di Pro+ per aprire la monografia completa di Pralsetinib: dosi, gravidanza e allattamento, effetti indesiderati, avvertenze e tutte le interazioni.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Paediatric dosing
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
Provi Pro+ gratis per 14 giorni sul web. Nessuna carta.
Altri farmaci della stessa classe
Domande frequenti
What is Pralsetinib used for?
Pralsetinib is a medicine in the class oncology. It is used for Non-small cell lung cancer, Thyroid cancer.
What side effects have been reported with Pralsetinib?
Musculoskeletal pain, Constipation, Hypertension, Diarrhea, Fatigue, Edema. Serious warning: May increase the risk of serious bacterial, fungal, viral and opportunistic infections, which can lead to hospitalization or death.
Can Pralsetinib be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm: in rats it caused malformations and embryo death below human exposure; no human data. Avoid in pregnancy; check pregnancy status. Women: non-hormonal contraception during treatment and for 2 weeks after (it may make hormonal methods fail); men: 1 week. Breastfeeding: Unsafe. No data on passage into milk; it is 97% protein bound, but its 22-hour half-life may allow build-up in the infant (LactMed). Do not breastfeed during treatment and for 1 week after the last dose.
What does Pralsetinib interact with?
MediHelp lists 16 known interactions for Pralsetinib. Major: 15 · Moderate: 1. The most serious include Amobarbital, Apalutamide, Carbamazepine.
Monografie complete, posologie e verifica delle interazioni nell'app MediHelp
Apra il riferimento completo, verifichi le interazioni tra più farmaci e usi gli strumenti di posologia nell'app MediHelp.
